# NCT03523585 (NCT03523585)

> DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03523585
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Daiichi Sankyo
- Conditions: Breast Cancer
- Interventions: Trastuzumab deruxtecan; Capecitabine; Lapatinib; Trastuzumab
- Enrollment: 608
- Primary outcome: Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine

## Commentary we found

- Podcasts: 14
- X threads: 14
- YouTube: 12

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct03523585

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03523585", "email": "<work email>"}; the inbox owner confirms by the emailed link.